Big Pharma · Neurology · United States

AstraZeneca — Neurology in United States

OncologyRare DiseaseImmunologyCardiometabolic
Commission a AstraZeneca report

AXLRx AstraZeneca intelligence — Neurology in United States: 1 report covering Neurology in United States.

All areas NeurologyImmunologyMetabolicOncologyRare Disease
Market: All United States
Market access — United States

Tagrisso dominant in first-line EGFR+ NSCLC; Alexion complement franchise (Ultomiris/Soliris) holds strong specialty access.

AXLRx reports featuring AstraZeneca — Neurology in United States
Alzheimer's Disease
CI
CI Neurology CI TeamLaunch Lead

US Alzheimer's Disease Competitive Intelligence

Lecanemab versus donanemab in early AD. CMS amyloid-confirmation coverage and ARIA monitoring as the access gate.

US In-Market Read report →